News coverage about Alnylam Pharmaceuticals (NASDAQ:ALNY) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.5056710418429 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Shares of Alnylam Pharmaceuticals (ALNY) opened at $144.16 on Wednesday. Alnylam Pharmaceuticals has a 12 month low of $46.90 and a 12 month high of $152.75. The stock has a market capitalization of $14,180.00, a PE ratio of -26.65 and a beta of 2.67. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm had revenue of $37.90 million during the quarter, compared to analyst estimates of $19.31 million. During the same period in the prior year, the business earned ($1.32) EPS. The business’s revenue for the quarter was up 116.6% compared to the same quarter last year. equities research analysts forecast that Alnylam Pharmaceuticals will post -6.88 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on the company. Credit Suisse Group set a $151.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. B. Riley reduced their price target on Alnylam Pharmaceuticals from $205.00 to $200.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. BMO Capital Markets reduced their price target on Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Chardan Capital restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, January 19th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $182.00 price target on shares of Alnylam Pharmaceuticals in a research report on Sunday, January 7th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $126.89.

In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the sale, the senior vice president now owns 17,749 shares of the company’s stock, valued at approximately $2,151,178.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $129.00, for a total value of $1,935,000.00. Following the completion of the sale, the director now directly owns 155,795 shares in the company, valued at approximately $20,097,555. The disclosure for this sale can be found here. Insiders sold a total of 57,994 shares of company stock worth $7,527,653 in the last three months. Company insiders own 4.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals (NASDAQ:ALNY) Receiving Somewhat Positive Press Coverage, Study Finds” was first published by Marea Informative and is owned by of Marea Informative. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.mareainformativa.com/2018/03/14/alnylam-pharmaceuticals-alny-given-coverage-optimism-rating-of-0-16-updated-updated-updated.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.